Company News for January 08, 2010 - Corporate Summary
• UBS (NYSE:UBS) upgraded Barclays (NYSE:BCS) to "buy" from "neutral"
• Macquarie downgraded Boeing (NYSE:BA) shares to "neutral" from "outperform." The company had risen to a 52-week high in yesterday's trade on improving passenger prospects for airlines
• TSMC (NYSE:TSM), the largest contract chipmaker, advised its December sales more than doubled from a year ago, pointing to a strong 2010 as new computers and other high-tech devices stimulate demand
• Marriott International (NYSE:MAR) said it expects its North American hotel revenues to show a slight improvement over prior projections, with hotel revenues per available room down 13-14% in the fourth quarter
• Intel (NASDAQ:INTC) introduced 32-nanometer edition processors including 11 mobile processors, six desktop processors, and four wireless adapters at the Las Vegas electronics show
• Apollo Group (NASDAQ:APOL) reported fiscal first quarter earnings of $1.47 versus $1.12, one penny higher than expected, on revenues which increased 30.8% from a year ago to $1.27 billion, beating estimates of $1.23 billion
• Lawson Software (NASDAQ:LWSN) reported inline fiscal second quarter earnings of 9 cents a share, on revenues of $184.4 million, down from $206.4 million which topped estimates of $176.21 million. The firm offered slightly lower than estimated third quarter guidance, but a revenue range surrounding Street expectations.
• Citigroup (NYSE:C) lowered earnings estimates for the following banks: Bank of America (NYSE:BAC), JP Morgan (NYSE:JPM), Morgan Stanley (NYSE:MS), and Goldman Sachs (NYSE:GS).
• Goldman Sachs (NYSE:GS) added Edward Lifesciences (NYSE:EW) to its Conviction Buy List, with the price target increased to $112, due to its significant new product cycle
• Goldman Sachs (NYSE:GS) removed Covidien (NYSE:COV) from its Conviction Buy List.
• Piper Jaffray (NYSE:PJC) reiterated its "overweight" rating on Telvent Git S.A. (NASDAQ:TLVT), raising its price target to $46 from $38
The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
